A recent study, the results of which were presented at the Endocrine Society conference (ENDO 2026), revealed that hormone therapy during menopause can significantly reduce the risk of bone density loss in women.
The researchers in the study relied on an analysis of data from 387 postmenopausal women who underwent bone density scans between 2021 and 2025. About a third of the participants received hormone therapy, while the rest did not receive any treatment, which allowed for a comparison of the effect of the treatment on bone health between the two groups.
The results showed that women undergoing hormone therapy had a 69% lower risk of bone mineral density loss in the spine and hip compared to those who did not. This positive association persisted even after accounting for other influencing factors such as age, number of years since menopause, vitamin D levels, smoking, and overall health.
The researchers noted that some women avoid hormone therapy due to concerns about its potential side effects, but the study's findings highlight its potential benefits, not only in relieving menopausal symptoms, but also in supporting bone health and reducing the risk of osteoporosis and fractures.
The study also pointed out that estrogen plays an important role in maintaining bone strength, in addition to its contribution to supporting cardiovascular health by regulating cholesterol levels and improving blood vessel elasticity, as well as its role in regulating body temperature and improving mood stability, which positively impacts the overall health of women after menopause.
